Association between dose reduction of renin-angiotensin-aldosterone system inhibitors before coronary artery angiography and acute kidney injury: A propensity score-matched study
Not Applicable
- Registration Number
- JPRN-UMIN000050823
- Lead Sponsor
- Graduate School of Medicine and Public Health, Kyoto University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 2007
Inclusion Criteria
Not provided
Exclusion Criteria
Patients undergoing dialysis within 3 days after admission were excluded. Patients with missing values for the primary diagnosis were also excluded because the primary diagnosis was treated as one of the explanatory variables in a previous study and may influence the incidence of AKI.
Study & Design
- Study Type
- Others,meta-analysis etc
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Pathophysiology RAAS inhibitor withdrawal contrast-induced nephropathy renal hemodynamics during coronary angiography.
Clinical guidelines RAAS inhibitor management peri-procedural contrast media acute kidney injury prevention.
Biomarkers predicting contrast-induced AKI risk patients on RAAS inhibitors undergoing coronary angiography.
Risk-benefit analysis continuing versus holding RAAS inhibitors before coronary angiography AKI cardiovascular outcomes.
Renal protective strategies contrast-induced AKI comparison RAAS inhibitor modulation hydration N-acetylcysteine.